NCT04106206View on ClinicalTrials.gov

A Safety Study of LY3372689 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 23, 2019

Primary Completion Date

February 12, 2020

Study Completion Date

February 12, 2020

Conditions
Healthy
Interventions
DRUG

LY3372689

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (1)

75247-4989

Covance, Dallas

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04106206 - A Safety Study of LY3372689 in Healthy Participants | Biotech Hunter | Biotech Hunter